Figure 2
![(A-C) Survival end points per 21 of 28-day arm (N = 43) and 28 of 28-day arm (N = 41); Kaplan-Meier estimates (ITT). (A) Time to progression. (B) Progression-free survival. (C) Overall survival. (D-F) Survival end points in the entire population (N = 84); Kaplan-Meier estimates (ITT). (D) Comparison between TTP on protocol and TTP on last prior line for all patients included in the study and for responders only (patients with either CR or VGPR or PR as per IMWG). (E) TTP In responders versus nonresponders as per IMWG criteria (eg, patients with stable disease including minimal response [SD]). (F) Overall survival in responders versus SD. O/N, number of events/number of patients in the group.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/121/11/10.1182_blood-2012-09-452375/4/1968f2.jpeg?Expires=1720818677&Signature=Idq5wqwql22KoLa-8eeKEmRQsdVnmXYfGbPHsumNTwegd61tJ64jBP~bevFd1sIgX3Lgz9QZNQxWZH9KXCViWpmxYlVsUDBAkjKEDylWeLyyZCBVHz~-TgL9e6WJ~y0uqrZaT3IYjpM1vMnsRbtZRPDVC5dM8JQYidIiMZ-wVq~IIeEAp1n~UgsGORyDVC4dvQl8usUVWt1iSXeatlOv6FWjnttVUIGnGc6~yUV8ZcK71KNGbjhqYmg956E5rtBffVVeUGemDlfn4~cUn8Ai29tMDfipE3IgPXtkuO7uQl6JeZQN~UOkYL0aSeQlA9dlkMVzCNouVfhGltpDfifV3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
(A-C) Survival end points per 21 of 28-day arm (N = 43) and 28 of 28-day arm (N = 41); Kaplan-Meier estimates (ITT). (A) Time to progression. (B) Progression-free survival. (C) Overall survival. (D-F) Survival end points in the entire population (N = 84); Kaplan-Meier estimates (ITT). (D) Comparison between TTP on protocol and TTP on last prior line for all patients included in the study and for responders only (patients with either CR or VGPR or PR as per IMWG). (E) TTP In responders versus nonresponders as per IMWG criteria (eg, patients with stable disease including minimal response [SD]). (F) Overall survival in responders versus SD. O/N, number of events/number of patients in the group.
